Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand.

Abstract:

PURPOSE:The genetic polymorphism was one of the major considerations for adjusting doses of warfarin in Thai individuals. As a result, new oral anticoagulants (NOACs) were introduced to achieve therapeutic goals in stroke prevention in atrial fibrillation (SPAF) patients. However, a cost-utility analysis in a population-specific model was lacking in Thailand. This study was performed to determine which NOACs yielded population-specific, cost-effective results for SPAF compared with warfarin from both governmental and societal perspectives in Thailand. METHODS:A simplified Markov health state model was constructed to calculate the lifetime cost, life-years saved, and quality-adjusted life-years (QALYs) gained. Asia-specific clinical event parameters were defined from systematic searches of PubMed. Cost and utility input was obtained from hospital based data collection. FINDINGS:Although NOACs produced more life-years saved and QALYs gained resulting from the base-case versus warfarin, the lifetime costs of new alternatives increased to >1.4 times the comparative cost of warfarin. This caused an incremental cost-effective ratio that exceeded Thailand's cost-effectiveness threshold. The probabilistic sensitivity analysis denoted the robustness of our model and revealed that dose-adjusted warfarin was the most cost-effective option in >99% of iterations. NOACs produced cost-effective results when the medication unit cost was decreased by at least 85%. IMPLICATIONS:According to the results of this first cost-utility analysis in Thailand, warfarin is still the most cost-effective medication for SPAF from any perspective in Thailand at the threshold recommended by our health technology assessment guidelines.

journal_name

Clin Ther

journal_title

Clinical therapeutics

authors

Jarungsuccess S,Taerakun S

doi

10.1016/j.clinthera.2014.08.016

subject

Has Abstract

pub_date

2014-10-01 00:00:00

pages

1389-94.e4

issue

10

eissn

0149-2918

issn

1879-114X

pii

S0149-2918(14)00554-2

journal_volume

36

pub_type

杂志文章
  • Treating hypertension to reduce cardiovascular risk: a Korean perspective.

    abstract:BACKGROUND:Hypertension usually clusters with other cardiovascular risk factors; however, it has not been reported whether hypertension treatment has an impact on the awareness and treatment of other cardiovascular risk factors such as diabetes mellitus and hypercholesterolemia. OBJECTIVE:To analyze the effect of hype...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2012.05.006

    authors: Kim KI,Kim CH

    更新日期:2012-07-01 00:00:00

  • Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test.

    abstract:BACKGROUND:Recombinant human growth hormone (GH) is used for the treatment of several conditions associated with growth retardation and metabolic dysfunction. These patients are typically diagnosed and treated from childhood, and treatment adherence in children might be problematic. To potentially improve treatment adh...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2009.12.014

    authors: Fuchs GS,Mikkelsen S,Knudsen TK,Kappelgaard AM

    更新日期:2009-12-01 00:00:00

  • Multi-indication Pharmacotherapeutic Multicriteria Decision Analytic Model for the Comparative Formulary Inclusion of Proton Pump Inhibitors in Qatar.

    abstract:PURPOSE:The formulary inclusion of proton pump inhibitors (PPIs) in the government hospital health services in Qatar is not comparative or restricted. Requests to include a PPI in the formulary are typically accepted if evidence of efficacy and tolerability is presented. There are no literature reports of a PPI scoring...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2016.03.004

    authors: Al-Badriyeh D,Alabbadi I,Fahey M,Al-Khal A,Zaidan M

    更新日期:2016-05-01 00:00:00

  • Prophylactic midazolam and clonidine for emergence from agitation in children after emergence from sevoflurane anesthesia: a meta-analysis.

    abstract:BACKGROUND:Emergence agitation (EA) after emergence from sevoflurane anesthesia is a common phenomenon in children. The efficacy of prophylactic midazolam or clonidine in preventing EA is controversial. OBJECTIVE:We performed a meta-analysis of clinical trials of the 2 drugs to evaluate their ability to prevent EA in ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.clinthera.2013.08.016

    authors: Zhang C,Li J,Zhao D,Wang Y

    更新日期:2013-10-01 00:00:00

  • Comparison of Continuous Infusion of Epinephrine and Phenylephrine on Hemodynamics During Spinal Anesthesia for Cesarean Delivery: A Randomized Controlled Trial.

    abstract:PURPOSE:Phenylephrine is a commonly used vasopressor for the treatment of spinal-induced hypotension in obstetric patients, but it is associated with reflex bradycardia and a corresponding decrease in cardiac output. This study aims to assess the effectiveness of continuous epinephrine versus phenylephrine infusion in ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2020.08.004

    authors: Wang YB,Yang ZY,Zhang WP

    更新日期:2020-10-01 00:00:00

  • Management of access to branded psychotropic medications in private health plans.

    abstract:BACKGROUND:In the past decade, health insurers have increased their reliance on cost control policies such as prior authorization and 3-tier formularies. Little is known about how these policies are being applied to psychotropic medications, many of which have low rates of patient adherence. OBJECTIVE:This study repor...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2007.02.011

    authors: Hodgkin D,Horgan CM,Garnick DW,Len Merrick E,Volpe-Vartanian J

    更新日期:2007-02-01 00:00:00

  • Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.

    abstract::The optimal antibiotic therapy for patients with acute bacterial exacerbations of chronic bronchitis (ABECB) who have failed to respond to previous oral antimicrobial therapy is not known; however, newer macrolide and fluoroquinolone antibiotics may be appropriate. This multicenter, randomized, double-masked, double-d...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/S0149-2918(99)80017-4

    authors: Lipsky BA,Unowsky J,Zhang H,Townsend L,Talbot GH

    更新日期:1999-06-01 00:00:00

  • Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

    abstract:OBJECTIVES:The aim of this study was to assess the therapeutic effectiveness of adefovir dipivoxil (ADV), administered in combination with lamivudine (LAM) or as monotherapy, and the rate of resistance to ADV, in hepatitis B e antigen (HBeAg)-negative adult patients with chronic hepatitis B virus (HBV) infection and cl...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2008.02.012

    authors: Pellicelli AM,Barbaro G,Francavilla R,Romano M,Barbarini G,Mazzoni E,Mecenate F,Paffetti A,Barlattani A,Struglia C,Villani R,Nauri L,Nosotti L,Armignacco O,Ferri F,Camporiondo MP,Soccorsi F,Club Epatologi Ospedalieri (C

    更新日期:2008-02-01 00:00:00

  • Pharmacokinetic bridging approach for developing biologics-delivery devices: a case study with a golimumab autoinjector.

    abstract:PURPOSE:This Phase 1 pharmacokinetic (PK) comparability study in healthy subjects was performed to compare the PK properties and tolerability of single-dose golimumab 100 mg delivered subcutaneously by an autoinjector device or by a standard needle and syringe that had been used for the subcutaneous (SC) delivery of go...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.clinthera.2014.09.012

    authors: Xu Z,Marciniak SJ Jr,Frederick B,Kim L,Zhuang Y,Davis HM,Zhou H

    更新日期:2015-02-01 00:00:00

  • Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension.

    abstract:BACKGROUND:Few studies have examined the relative efficacy and tolerability of antihypertensive drug classes in Chinese populations. OBJECTIVE:This study compared the efficacy, tolerability, and duration of antihypertensive effect of amlodipine besylate and enalapril in Chinese patients with hypertension, including el...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/s0149-2918(04)80145-0

    authors: Tomlinson B,Woo J,Thomas GN,Chau YM,Critchley JA

    更新日期:2004-08-01 00:00:00

  • New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.

    abstract:PURPOSE:Interferon injectables and glatiramer acetate have served as the primary disease-modifying treatments for multiple sclerosis (MS) since their introduction in the 1990s and are first-line treatments for relapsing-remitting forms of MS (RRMS). Many new drug therapies were launched since early 2010, expanding the ...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2015.03.001

    authors: English C,Aloi JJ

    更新日期:2015-04-01 00:00:00

  • Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.

    abstract:PURPOSE:Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis compared the efficacy and safety of tofacitinib with biologic disease-modifying antirheumatic drugs in patients with RA and a prior inadequate response (IR) to tumor necrosis factor inhibitors (TNFi). ME...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.clinthera.2016.11.004

    authors: Vieira MC,Zwillich SH,Jansen JP,Smiechowski B,Spurden D,Wallenstein GV

    更新日期:2016-12-01 00:00:00

  • Management of worsening multiple sclerosis with mitoxantrone: a review.

    abstract:BACKGROUND:Mitoxantrone, an intravenously administered immunosuppressant that inhibits T-cell, B-cell, and macrophage proliferation, is indicated for reducing neurologic disability and relapse frequency in patients with secondary progressive multiple sclerosis (SPMS), progressive relapsing MS, or worsening relapsing-re...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2006.04.013

    authors: Fox EJ

    更新日期:2006-04-01 00:00:00

  • Treatment of chancroid with spectinomycin or co-trimoxazole.

    abstract::Chancroid, the third most prevalent venereal disease in Thailand, was treated with a single 2-gm dose of spectinomycin, or two tablets of co-trimoxazole (trimethoprim-sulfamethoxazole) twice daily for seven days. The differences in cure rates between the two groups were statistically significant. The chancroidal ulcer...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Traisupa A,Ariyarit C,Metheeprapha C,Buatiang A,Sungthong P

    更新日期:1990-05-01 00:00:00

  • Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa.

    abstract::Inhibitors of platelet glycoprotein (GP) IIb-IIIa have been demonstrated to be effective in controlling acute cardiac complications in patients presenting with acute ischemic coronary syndromes (AICS). Since patients with atherosclerotic coronary vascular disease may present with AICS on multiple occasions, it is impo...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/S0149-2918(00)88273-9

    authors: Lorenz TJ,Macdonald F,Kitt MM

    更新日期:1999-01-01 00:00:00

  • The efficacy of two doses of omeprazole for short- and long-term peptic ulcer treatment in the elderly.

    abstract::This study evaluated the efficacy, safety, and most suitable dose of omeprazole in short-term acute treatment (4 weeks) and maintenance treatment (6 months) of patients older than 60 years of age with endoscopically diagnosed gastric ulcer (GU) or duodenal ulcer (DU). This randomized, prospective study included 156 pa...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Pilotto A,Di Mario F,Battaglia G,Vigneri S,Leandro G,Franceschi M,De Boni M,Grasso A,Vianello F,Naccarato R

    更新日期:1994-11-01 00:00:00

  • Albendazole in the treatment of intestinal helminthiasis in children.

    abstract::One hundred sixteen children between 2 and 15 years of age entered a clinical trial of albendazole after examination of their stools revealed ova of one or more intestinal helminths. The drug was administered as a single 400-mg dose (20 ml of 2% suspension) to all the patients except those having Hymenolepis nana infe...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Prasad R,Mathur PP,Taneja VK,Jagota SC

    更新日期:1985-01-01 00:00:00

  • Effects of an Extract of Salmon Milt on Symptoms and Serum TNF and Substance P in Patients With Fibromyalgia Syndrome.

    abstract:PURPOSE:The aim of this study was to evaluate the effects of a dietary supplement containing primarily an extract of salmon's milt (semen) on symptoms and blood levels of proinflammatory molecules in patients with fibromyalgia syndrome (FMS), a chronic, painful musculoskeletal disease without a distinct pathogenesis or...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.clinthera.2019.05.019

    authors: Tsilioni I,Pipis H,Freitag MSC,Izquierdo MDC,Freitag K,Theoharides TC

    更新日期:2019-08-01 00:00:00

  • The bad taste of medicines: overview of basic research on bitter taste.

    abstract:BACKGROUND:Many active pharmaceutical ingredients taste bitter and thus are aversive to children as well as many adults. Encapsulation of the medicine in pill or tablet form, an effective method for adults to avoid the unpleasant taste, is problematic for children. Many children cannot or will not swallow solid dose fo...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2013.06.007

    authors: Mennella JA,Spector AC,Reed DR,Coldwell SE

    更新日期:2013-08-01 00:00:00

  • An economic evaluation of oral compared with intravenous ganciclovir for maintenance treatment of newly diagnosed cytomegalovirus retinitis in AIDS patients.

    abstract::This prospective, clinical economic study was done to determine the cost impact of oral compared with intravenous (i.v.) ganciclovir for the maintenance treatment of newly diagnosed cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Efficacy and safety data were extracted from ...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/s0149-2918(96)80036-1

    authors: Sullivan SD,Mozaffari E,Johnson ES,Wolitz R,Follansbee SE

    更新日期:1996-05-01 00:00:00

  • Managing Procedural Pain in the Neonate Using an Opioid-sparing Approach.

    abstract:PURPOSE:Pain in the neonate is often challenging to assess but important to control. Physicians often must balance the need for optimal pain control with the need to minimize oversedation and prolonged opioid use. Both inadequate pain control and overuse of opioids can have long-term consequences, including poor develo...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2019.07.014

    authors: Squillaro A,Mahdi EM,Tran N,Lakshmanan A,Kim E,Kelley-Quon LI

    更新日期:2019-09-01 00:00:00

  • Telbivudine for the management of chronic hepatitis B virus infection.

    abstract:BACKGROUND:Telbivudine (LdT) is an L-nucleoside that is structurally related to lamivudine. It is highly selective for hepatitis B virus (HBV) and inhibits viral DNA synthesis. LdT was approved by the US Food and Drug Administration on October 25, 2006, for the treatment of chronic HBV infection in adults who have acti...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2007.12.032

    authors: Matthews SJ

    更新日期:2007-12-01 00:00:00

  • Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.

    abstract:BACKGROUND:Most patients with hypertension in the United States and Europe fail to achieve the recommended target blood pressure (BP) of <140/90 mm Hg. Combination therapy is required in approximately two thirds of all patients whose BP is >20/10 mm Hg above the goal. Combination therapy with agents having complementar...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.clinthera.2007.02.003

    authors: Poldermans D,Glazes R,Kargiannis S,Wernsing M,Kaczor J,Chiang YT,Yen J,Gamboa R,Fomina I

    更新日期:2007-02-01 00:00:00

  • Trends in off-label beta-blocker use: a secondary data analysis.

    abstract:BACKGROUND:The off-label use of beta-blockers might be prevalent, but no studies have provided empiric data on the off-label use based on utilization data. OBJECTIVE:This secondary data analysis was conducted to describe the trends of off-label use of beta-blockers among ambulatory visits made to office-based physicia...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2006.10.015

    authors: Lin HW,Phan K,Lin SJ

    更新日期:2006-10-01 00:00:00

  • Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin.

    abstract::This article reviews the administration, efficacy, and safety of prophylactic intravenous immunoglobulin in patients with secondary immunodeficiency and those undergoing allogeneic bone marrow transplantation. Associated infections in these immunosuppressed patients are examined as they relate to transfusion-associate...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/s0149-2918(96)80204-9

    authors: Sullivan KM

    更新日期:1996-01-01 00:00:00

  • Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris.

    abstract::A four-week crossover study to compare the efficacy of an acne cleanser containing 2% salicylic acid with that of a 10% benzoyl peroxide wash was conducted in 30 patients with acne vulgaris. The results demonstrated that only patients treated with the salicylic acid cleanser had a significant reduction in comedones. P...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Shalita AR

    更新日期:1989-03-01 00:00:00

  • Comparison of once-daily cephalosporin regimens for community-acquired lower respiratory tract infections in patients with chronic lung disease.

    abstract::The efficacy of cefonicid and of ceftriaxone, administered once daily for the treatment of lower respiratory tract bacterial infections (pneumonia or bronchitis), was evaluated and compared in 118 patients with chronic lung disease. The patients were randomly assigned to receive 1 gm of either drug, intravenously or i...

    journal_title:Clinical therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: McCabe RE,Schlossberg D,Donowitz GR,Scheld WM,Zellner SR,Lindenberg LB,Armstrong JH,Ein ME

    更新日期:1989-05-01 00:00:00

  • Rotavirus live, oral, pentavalent vaccine.

    abstract:BACKGROUND:On February 3, 2006, the US Food and Drug Administration (FDA) approved a live, oral, pentavalent (G1-G4, P1[8]) human-bovine reassortant rotavirus vaccine for the prevention of rotavirus gastroenteritis (RVGE) in infants in the United States. The Advisory Committee of Immunization Practices of the Centers f...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章,评审

    doi:10.1016/j.clinthera.2007.12.018

    authors: Tom-Revzon C

    更新日期:2007-12-01 00:00:00

  • Effects of benzothiazepine derivative (CRD-401) on blood pressure, excretion of electrolytes, and plasma renin activity.

    abstract::A benzothiazepine derivative, CRD-401, was administered orally in a dosage of 60 to 120 mg/day to 14 patients with various renal diseases. The systolic pressure was lowered slightly in some cases after administration of CRD-401. Urine volume and urinary excretion of electrolytes were increased by the drug in most pati...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:

    authors: Funyu T,Nigawara K,Ohno K,Hamada W,Yagihashi Y

    更新日期:1981-01-01 00:00:00

  • Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database.

    abstract:BACKGROUND:The utilization pattern of dronedarone was unknown, especially regarding prescribers' compliance with the product's prescribing information (PI) following its availability and the implementation of the Food and Drug Administration-approved risk evaluation and mitigation strategy for the drug in the United St...

    journal_title:Clinical therapeutics

    pub_type: 杂志文章

    doi:10.1016/j.clinthera.2011.08.013

    authors: Gao S,Juhaeri J,Schiappacasse HA,Koren AT,Dai WS

    更新日期:2011-10-01 00:00:00